Logo image of ENDP

ENDO INTERNATIONAL PLC (ENDP) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ENDP - IE00BJ3V9050 - Common Stock

0.2926 USD
-0.02 (-5%)
Last: 8/25/2022, 10:28:44 PM
0.26 USD
-0.03 (-11.14%)
After Hours: 8/25/2022, 10:28:44 PM

ENDP Key Statistics, Chart & Performance

Key Statistics
Market Cap68.80M
Revenue(TTM)2.78B
Net Income(TTM)-2.60B
Shares235.14M
Float231.41M
52 Week High7.07
52 Week Low0.28
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)2.33
PE0.13
Fwd PE0.33
Earnings (Next)11-07
IPO2014-03-03
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
ENDP short term performance overview.The bars show the price performance of ENDP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

ENDP long term performance overview.The bars show the price performance of ENDP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ENDP is 0.2926 USD. In the past month the price decreased by -45.05%. In the past year, price decreased by -87.39%.

ENDO INTERNATIONAL PLC / ENDP Daily stock chart

ENDP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ENDP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ENDP. ENDP has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ENDP Financial Highlights

Over the last trailing twelve months ENDP reported a non-GAAP Earnings per Share(EPS) of 2.33. The EPS decreased by -12.08% compared to the year before.


Industry RankSector Rank
PM (TTM) -93.31%
ROA -40.81%
ROE N/A
Debt/Equity -2.52
Chartmill High Growth Momentum
EPS Q2Q%-95.38%
Sales Q2Q%-20.27%
EPS 1Y (TTM)-12.08%
Revenue 1Y (TTM)-1.56%

ENDP Forecast & Estimates

7 analysts have analysed ENDP and the average price target is 1.02 USD. This implies a price increase of 248.6% is expected in the next year compared to the current price of 0.2926.

For the next year, analysts expect an EPS growth of -57.56% and a revenue growth -18.43% for ENDP


Analysts
Analysts42.86
Price Target1.02 (248.6%)
EPS Next Y-57.56%
Revenue Next Year-18.43%

ENDP Ownership

Ownership
Inst Owners0%
Ins Owners2.12%
Short Float %N/A
Short RatioN/A

About ENDP

Company Profile

ENDP logo image Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 3,103 full-time employees. The company went IPO on 2014-03-03. The firm operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. The firm's Generic Pharmaceuticals segment consists of a product portfolio, including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.

Company Info

ENDO INTERNATIONAL PLC

First Floor, Minerva House, Simmonscourt Road, Dublin 4

DUBLIN DUBLIN 19355 IE

CEO: Blaise Coleman

Employees: 3103

ENDP Company Website

Phone: 35312682000.0

ENDO INTERNATIONAL PLC / ENDP FAQ

Can you describe the business of ENDO INTERNATIONAL PLC?

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 3,103 full-time employees. The company went IPO on 2014-03-03. The firm operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. The firm's Generic Pharmaceuticals segment consists of a product portfolio, including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.


What is the stock price of ENDO INTERNATIONAL PLC today?

The current stock price of ENDP is 0.2926 USD. The price decreased by -5% in the last trading session.


What is the dividend status of ENDO INTERNATIONAL PLC?

ENDP does not pay a dividend.


What is the ChartMill technical and fundamental rating of ENDP stock?

ENDP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy ENDP stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ENDP.


Can you provide the market cap for ENDO INTERNATIONAL PLC?

ENDO INTERNATIONAL PLC (ENDP) has a market capitalization of 68.80M USD. This makes ENDP a Micro Cap stock.


Can you provide the upcoming earnings date for ENDO INTERNATIONAL PLC?

ENDO INTERNATIONAL PLC (ENDP) will report earnings on 2022-11-07.